ProfileGDS5678 / 1437080_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 97% 96% 96% 97% 97% 96% 97% 97% 96% 97% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.9643196
GSM967853U87-EV human glioblastoma xenograft - Control 29.1025596
GSM967854U87-EV human glioblastoma xenograft - Control 39.2161797
GSM967855U87-EV human glioblastoma xenograft - Control 49.2325896
GSM967856U87-EV human glioblastoma xenograft - Control 59.1148796
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.0438597
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.0739697
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.8554396
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.0899297
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.1819197
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.9619796
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.1446497
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.9638896
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0413996